phase 3 trial: Amgen drug (trebanaib +) delays regrowth of ovarian cancer, survival rate still unclear Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, June 13, 2013

phase 3 trial: Amgen drug (trebanaib +) delays regrowth of ovarian cancer, survival rate still unclear



 Business
Phase 3 TRINOVA-1 trial studying trebanaib plus paclitaxel 

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.